#USA #Needham #Digital Pathology #Evident #Pramana POD

Evident Expands Digital Pathology Solutions with Pramana™ POD

Evident has made a significant stride in the realm of digital pathology by introducing its latest innovation, the Pramana™ POD (Whole Slide Imaging - WSI) scanner. Targeted towards small to medium-sized laboratories, this state-of-the-art benchtop system is designed to help labs streamline their imaging processes while ensuring high-quality results with minimal operator intervention.

Unveiled at the recent Pathology Visions 2026 conference, the Pramana™ POD scanner promises to revolutionize the way pathology samples are digitized. As the demand for digital workflows continues to rise, particularly in an era marked by increasing operational requirements and case loads, laboratories are seeking robust and dependable imaging solutions. The introduction of the Pramana™ POD directly addresses this need, offering automatic imaging capabilities that facilitate the generation of whole slide images necessary for pathologists' analyses.

According to Prasanth Perugupalli, Vice President of Digital Pathology at Evident, the Pramana WSI technology has garnered immense approval from pathology labs across university medical centers and laboratory networks throughout the United States. With an integrated quality assurance system throughout the imaging process, this technology not only enhances the quality of imaging but also mitigates the need for post-scan quality checks, resulting in cost savings and increased efficiency.

The Pramana™ POD scanner excels in automating the imaging process, utilizing an advanced tissue localization system, comprehensive label detection, and automated focal plane selection alongside scanning profiles. This integrated quality assessment ensures that generated images are immediately ready for pathologists, pinpointing any areas warranting added scrutiny. Moreover, the volumetric imaging functionality captures multiple focal planes, allowing users to select sharply focused information across the entire scanned area, achieving true 40X imaging at an impressive rate of 25 slides per hour.

Designed to accommodate various applications in brightfield imaging, the series of Pramana WSI scanners is particularly well-suited for histopathology, core biopsies, hematology, cytology, and microbiology workflows. Perugupalli emphasizes that while scientific advancements progress swiftly, laboratory infrastructure often lags behind. The Pramana™ POD allows smaller laboratories to evolve in tandem with their operational requirements, thereby fostering adaptability in an ever-changing clinical landscape.

Evident remains committed to pushing boundaries in imaging technology. With over a century of expertise under the Olympus name, the company has continued its legacy by offering cutting-edge imaging solutions that merge renowned optics with avant-garde digital innovations. The Pramana™ POD scanner is a vital component of Evident's extensive portfolio in life sciences, which supports research, clinical diagnostics, and education through a diverse range of imaging modalities.

For more detailed information about the Pramana™ POD bench scanner, including specifications and use cases, visit EvidentScientific.com.

About Evident

Evident, headquartered in Tokyo, has established industry standards in optical precision through microscopy for over a century. The company's mission is to help scientists, physicians, and engineers illuminate the previously unseen with advanced imaging solutions. Their comprehensive offerings span essential brightfield microscopy to complex fluorescence advanced analysis, including digital pathology solutions.

With research and development facilities and manufacturing operations in Japan, the United States, Germany, and China, Evident leverages global expertise to deliver high-quality imaging tools that enable groundbreaking discoveries and innovative therapies in various fields. To learn more about Evident and its offerings, visit EvidentScientific.com.

This press release is for research purposes only and should not be used in diagnostic procedures. Future clinical availability is subject to applicable regulatory approvals, and regulatory status may vary by country. Performance may differ based on sample type and workflow.